Rehospitalization risk with second-generation and depot antipsychotics

Annals of Clinical Psychiatry

Volumn 15, Issue 1, 2003, Pages 23-31

  Conley, Robert R ^a,c   Kelly, Deanna L ^a   Love, Raymond C ^b   McMahon, Robert P ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Atypical antipsychotics; Depot antipsychotics; Rehospitalization; Schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; OLANZAPINE; RISPERIDONE;

ADULT; CONFERENCE PAPER; DEMOGRAPHY; DRUG TOLERABILITY; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; PRIORITY JOURNAL; PROGNOSIS; RISK; SCHIZOPHRENIA; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DATA COLLECTION; DELAYED-ACTION PREPARATIONS; FEMALE; FLUPHENAZINE; HALOPERIDOL; HUMANS; MALE; PATIENT READMISSION; PIRENZEPINE; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038341023     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023276509470     Document Type: Conference Paper

References (47)

1. Atakan Z, Cliff G, Cooper JE: Can psychiatrists predict the one-year outcome of schizophrenia? Soc Psychiatry Psychiatr Epidemiol 1990; 25(3):117-124
2. Olfson M, Mechanic D, Boyer CA, Hansell S, Walkup J, Weiden PJ: Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis 1999; 187(12):721-729
3. Russo J, Roy-Byrne P, Jaffe C, Ries R, Dagadakis C, Avery D: Psychiatric status, quality of life, and level of care as predictors of outcomes of acute inpatient treatment. Psychiatr Serv 1997; 48(11):1427-1434
4. Swett C: Symptom severity and number of previous psychiatric admissions as predictors of readmission. Psychiatr Serv 1995; 46(5):482-485
5. Gupta S, Hendricks S, Kenkel AM, Bhatia SC, Haffke EA: Relapse in schizophrenia: Is there a relationship to substance abuse?. Schizophr Res 1996; 20:153-156
6. Sullivan G, Wells KB, Morgenstern H, Leake B: Identifying modifiable risk factors for rehospitalization: A case control study of seriously mental ill persons in Mississippi. Am J Psychiatry 1995; 152(12):1749-1756
7. Neale MS, Rosenheck RA: Therapeutic alliance and outcome in a VA intensive case management program. Psychiatr Serv 1995; 46(7):719-721
8. Vaughn CE, Leff JP: The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976; 129:125-137
9. Weiden P, Aquila R, Standard J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57(Suppl. 11):53-60
10. Gerlach J: Depot neuroleptics in relapse prevention: Avantages and disadvantages. Int Clin Psychopharmacol 1995; 9(Suppl 5):17-20
11. Barnes TR, Curson DA: Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10(6):464-479
12. Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB: Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980; 37(1):16-24
13. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR: Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8(1):55-66
14. Lehman AF, Steinwachs DM: At issue: Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24:1-10
15. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP: The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999; 60:649-657
16. Citrome L, Levine J, Allingham B: Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull 1996; 32(3):321-326
17. Kuno E, Rothbard AB: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 2002; 159:567-572
18. Tavcar R, Dernovsek MZ, Zvan V: Choosing antipsychotic maintenance therapy - A naturalistic study. Pharmacopsychiatry 2000; 33(2):66-71
19. Jibson MD, Tandon R: New atypical antipsychotic medications. J Psychiatr Res 1998; 32:215-228
20. Gaebel W: Towards the improvement of compliance: The significance of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 1997; 12(Suppl 1):S37-S42
21. Tran PV, Dellva MA, Tollefson GD, Wently AL, Beasley CM, Jr: Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998; 172:499-505
22. Conley RR, Love RC, Kelly DL, Bartko JJ: Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999; 156:863-868
23. Essock SM, Hargreaves WA, Covell NH, Goethe J: Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull 1996; 32(4):683-697
24. Hogarty GE: Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 1993; 54(Suppl 3):18-23
25. Rabinowitz J, Licthenberg P, Kaplan Z, Mark M, Nahon D, Davidson M: Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158:266-269
26. Hogarty GE, Ulrich RF: The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998; 32:243-250
27. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG: Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 1997; 54(5):453-463
28. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR: Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: Comparison with risperidone. Am J Health Syst Pharm 1998; 55(Suppl 4):17-19
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
30. Prentice RL: Linear rank tests with right censored data. Biometrika 1978; 65:167-179
31. Cox DR: Regression models with life tables. J R Stat Soc 1972; 34:187-220
32. Aickin M, Gensler H: Adjusting for multiple testing when reporting research results: The Bonferroni vs. Holm methods. Am J Public Health 1996; 86:726-728
33. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9):789-796
34. Conley RR, Buchanan RW: Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23(4):663-674
35. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 1997; 58(12):538-546
36. Tollefson GD, Sanger TM: Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154(4):466-474
37. Patel NC, Dorson PG, Edwards N, Mendelson S, Crismon ML: One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv 2002; 53:891-893
38. Mahmoud R, Engelhart L, Ollendorf D, Oster G: The Risperidone Outcomes Study of Effectiveness (ROSE): A model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry 1999; 60(Suppl 3):42-47
39. Desai NM, Huq Z, Martin SD, McDonald G: Switching from depot antipsychotics to risperidone: Results of a study of chronic schizophrenia. The schizophrenia treatment and assessment group. Adv Ther 1999; 16(2):78-88
40. McKane JP, Robinson AD, Wiles DH, McCreadie RG, Stirling GS: Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychiatry 1987; 151:333-336
41. Bransgrove LL, Kelly NW: Movement disorders in patients treated with long-acting injectable antipsychotic drugs. Am J Hosp Pharm 1994; 51(7):895-899
42. Masimiremba CM, Hasler JA: Genetic polymorphism of drug metabolism enzymes in African populations: Implications for the use of neuroleptics and antidepressants. Brain Res Bull 1997; 44(5):561-571
43. Bertilsson L: Geographical/interracial differences in polymorphic drug oxidation, current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29:192-209
44. Tunnicliffe S, Harrison G, Standen PJ: Factors affecting compliance with depot injection treatment in the community. Soc Psychiatry Psychiatr Epidemiol 1992; 27(5):230-233
45. Segal SP, Bola JR, Watson MA: Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996; 47(3):282-286
46. Glazer WM, Morganstern H, Doucette J: Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994; 45(1):38-42
47. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry 1999; 60(Suppl 11):3-80